THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Clinical trials for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) explained in plain language.
Never miss a new study
Get alerted when new THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) trials appear
Sign up with your email to follow new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could reduce need for plasma exchange in rare blood disorder
Disease control CompletedThis study tested a drug called TAK-755 in 29 adults with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The goal was to see if TAK-755, along with standard immune-suppressing drugs, could control the disease with little or no pl…
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New enzyme therapy shows promise in controlling rare blood clotting disorder
Disease control CompletedThis study tested a medicine called BAX 930 in 52 people born with severe TTP, a rare condition that causes dangerous blood clots. The medicine replaces a missing enzyme to prevent or treat sudden flare-ups. Participants received either BAX 930 or standard treatment for 6 months,…
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC